| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 From the Department of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee; and 2 Alcon Laboratories, Inc., Fort Worth, Texas.
PURPOSE. The inhibition of angiogenesis by angiostatic steroids has been demonstrated in a variety of systems, including rabbit and rat cornea. There is considerable interest in the therapeutic potential of this class of compounds for angiogenic ocular conditions such as diabetic retinopathy, macular degeneration, and retinopathy of prematurity (ROP). This study was designed to test the capacity of an angiostatic steroid, anecortave acetate, to inhibit retinal neovascularization using a rat model of ROP and to investigate the mechanism of the effect.
METHODS. At birth, rats were placed in an atmosphere of varying oxygen that produces retinal neovascular changes that approximate human ROP. The rats then received intravitreal injections of either anecortave acetate or vehicle at varying times, and all were subsequently placed in room air. Retinas were assessed for plasminogen activator inhibitor (PAI)-1 mRNA level by RNase protection assay at 1, 2, and 3 days after injection and for normal and abnormal blood vessel growth 3 days later.
RESULTS. A significant reduction in the severity of abnormal retinal neovascularization was observed in the steroid-treated eyes compared with vehicle-injected eyes in ROP rats, yet the extent of normal total retinal vascular area was not significantly different. The drug had no effect on either retinal vascular area or neovascularization when tested in room air–raised control rats. Drug-injected eyes demonstrated a six- to ninefold increase in PAI-1 mRNA at 1 to 3 days after injection.
CONCLUSIONS. This study represents the first therapeutic effect of an angiostatic steroid in an animal model of neovascular retinopathy. Additionally, the induction of PAI-1 indicates a mechanism of action for this class of compounds, and this is a novel finding in vivo. Because anecortave acetate significantly inhibited pathologic retinal angiogenesis in this model, while not significantly affecting normal intraretinal vessels, it holds therapeutic potential for a number of human ocular conditions in which angiogenesis plays a critical pathologic role.
This article has been cited by other articles:
|
|
 |
|
  J. M. Barnett, G. W. McCollum, J. A. Fowler, J. J.-W. Duan, J. D. Kay, R.-Q. Liu, D. P. Bingaman, and J. S. Penn Pharmacologic and Genetic Manipulation of MMP-2 and -9 Affects Retinal Neovascularization in Rodent Models of OIR Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 907 - 915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Arroyo A 76-year-old man with macular degeneration. JAMA, May 24, 2006; 295(20): 2394 - 2406. [Full Text] [PDF]
|
|
|
|
|
|
M.-E. Jockovich, T. G. Murray, E. Escalona-Benz, E. Hernandez, and W. Feuer Anecortave Acetate as Single and Adjuvant Therapy in the Treatment of Retinal Tumors of LHBETATAG Mice. Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1264 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Penn, G. W. McCollum, J. M. Barnett, X. Q. Werdich, K. A. Koepke, and V. S. Rajaratnam Angiostatic Effect of Penetrating Ocular Injury: Role of Pigment Epithelium-Derived Factor Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 405 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U H M Spandau, G Sauder, U Schubert, H-P Hammes, and J B Jonas Effect of triamcinolone acetonide on proliferation of retinal endothelial cells in vitro and in vivo Br. J. Ophthalmol., June 1, 2005; 89(6): 745 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J B Jonas, I Kreissig, and R F Degenring Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration Br. J. Ophthalmol., December 1, 2004; 88(12): 1557 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Franklin, T. L. Jetton, C. L. Kuchemann, S. R. Russell, and E. C. Kohn CAI Is a Potent Inhibitor of Neovascularization and Imparts Neuroprotection in a Mouse Model of Ischemic Retinopathy Invest. Ophthalmol. Vis. Sci., October 1, 2004; 45(10): 3756 - 3766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Penn and V. S. Rajaratnam Inhibition of Retinal Neovascularization by Intravitreal Injection of Human rPAI-1 in a Rat Model of Retinopathy of Prematurity Invest. Ophthalmol. Vis. Sci., December 1, 2003; 44(12): 5423 - 5429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Ciulla, A. G. Amador, and B. Zinman Diabetic Retinopathy and Diabetic Macular Edema: Pathophysiology, screening, and novel therapies Diabetes Care, September 1, 2003; 26(9): 2653 - 2664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T A Ciulla, M H Criswell, R P Danis, M Fronheiser, P Yuan, T A Cox, K G Csaky, and M R Robinson Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants Br. J. Ophthalmol., August 1, 2003; 87(8): 1032 - 1037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. McGuire, T. R. Jones, N. Talarico, E. Warren, and A. Das The Urokinase/Urokinase Receptor System in Retinal Neovascularization: Inhibition by A6 Suggests a New Therapeutic Target Invest. Ophthalmol. Vis. Sci., June 1, 2003; 44(6): 2736 - 2742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Lambert, C. Munaut, P. Carmeliet, R. D. Gerard, P. J. Declerck, A. Gils, C. Claes, J.-M. Foidart, A. Noel, and J.-M. Rakic Dose-Dependent Modulation of Choroidal Neovascularization by Plasminogen Activator Inhibitor Type I: Implications for Clinical Trials Invest. Ophthalmol. Vis. Sci., June 1, 2003; 44(6): 2791 - 2797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J B Jonas, I Kreissig, P Hugger, G Sauder, S Panda-Jonas, and R Degenring Intravitreal triamcinolone acetonide for exudative age related macular degeneration Br. J. Ophthalmol., April 1, 2003; 87(4): 462 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J B Jonas, I Kreissig, and R Degenring Intraocular pressure after intravitreal injection of triamcinolone acetonide Br. J. Ophthalmol., January 1, 2003; 87(1): 24 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Sennlaub, Y. Courtois, and O. Goureau Inducible Nitric Oxide Synthase Mediates Retinal Apoptosis in Ischemic Proliferative Retinopathy J. Neurosci., May 15, 2002; 22(10): 3987 - 3993. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
